A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 mg in Patients With Relapsing-remitting Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 14 Jul 2015
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Acronyms FIRST LATAM
- Sponsors Novartis
- 14 Jul 2015 Results published in the Advances in Therapy.
- 04 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Feb 2014 Actual patient number changed from 158 to 161 as reported by ClinicalTrials.gov record.